{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:45:21Z","timestamp":1794336321714,"version":"4.9.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA006927"],"award-info":[{"award-number":["P30CA006927"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007322","name":"Fox Chase Cancer Center","doi-asserted-by":"publisher","award":["P30CA006927"],"award-info":[{"award-number":["P30CA006927"]}],"id":[{"id":"10.13039\/100007322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1053\/j.gastro.2025.07.004","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T20:28:28Z","timestamp":1763152108000},"page":"34-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Gastroenteropancreatic Neuroendocrine Tumors"],"prefix":"10.1053","volume":"170","author":[{"given":"Namrata","family":"Vijayvergia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryson W.","family":"Katona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2025.07.004_bib1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cncr.31124","article-title":"Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases","volume":"124","author":"Dasari","year":"2018","journal-title":"Cancer"},{"key":"10.1053\/j.gastro.2025.07.004_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1053\/j.gastro.2025.07.004_bib3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-81518-4","article-title":"Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms","volume":"14","author":"Uhlig","year":"2024","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2025.07.004_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41571-022-00696-0","article-title":"Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies","volume":"20","author":"Kawasaki","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.thorsurg.2021.05.005","article-title":"Neuroendocrine tumors of the lung","volume":"31","author":"Randhawa","year":"2021","journal-title":"Thorac Surg Clin"},{"key":"10.1053\/j.gastro.2025.07.004_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11864-021-00866-9","article-title":"Systemic treatment of gastroenteropancreatic neuroendocrine carcinoma","volume":"22","author":"Mollazadegan","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib8","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.cgh.2018.12.017","article-title":"Incidence trends of gastroenteropancreatic neuroendocrine tumors in the United States","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.07.004_bib9","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/MPA.0000000000001431","article-title":"Racial differences in the incidence and survival of patients with neuroendocrine tumors","volume":"48","author":"Shen","year":"2019","journal-title":"Pancreas"},{"key":"10.1053\/j.gastro.2025.07.004_bib10","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.cgh.2009.11.009","article-title":"High-definition colonoscopy detects colorectal polyps at a higher rate than standard white-light colonoscopy","volume":"8","author":"Buchner","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.07.004_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/17446651.2023.2237593","article-title":"Understanding the increasing incidence of neuroendocrine tumors","volume":"18","author":"Pathak","year":"2023","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1053\/j.gastro.2025.07.004_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1053\/j.gastro.2025.07.004_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4253\/wjge.v14.i5.267","article-title":"Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms","volume":"14","author":"Canakis","year":"2022","journal-title":"World J Gastrointest Endosc"},{"key":"10.1053\/j.gastro.2025.07.004_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000457956","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification","volume":"105","author":"Perren","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.gastro.2025.07.004_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/PAP.0000000000000256","article-title":"An algorithmic immunohistochemical approach to define tumor type and assign site of origin","volume":"27","author":"Bellizzi","year":"2020","journal-title":"Adv Anat Pathol"},{"key":"10.1053\/j.gastro.2025.07.004_bib16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/gastroent13010014","article-title":"What gastroenterologists should know about carcinoid syndrome","volume":"13","author":"Magi","year":"2022","journal-title":"Gastroenterol Insights"},{"key":"10.1053\/j.gastro.2025.07.004_bib18","article-title":"Carcinoid syndrome: a review","volume":"12","author":"Gade","year":"2020","journal-title":"Cureus"},{"key":"10.1053\/j.gastro.2025.07.004_bib19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000225948","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers","volume":"90","author":"O'Toole","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.gastro.2025.07.004_bib20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0004563215613109","article-title":"Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement","volume":"53","author":"Adaway","year":"2016","journal-title":"Ann Clin Biochem"},{"key":"10.1053\/j.gastro.2025.07.004_bib21","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2024. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1448. Accessed June 20, 2024."},{"key":"10.1053\/j.gastro.2025.07.004_bib22","first-page":"359","article-title":"Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors","volume":"74","author":"Chauhan","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.gastro.2025.07.004_bib23","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/ERC-17-0269","article-title":"Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame","volume":"25","author":"Marotta","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.gastro.2025.07.004_bib24","article-title":"Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2025.07.004_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ecl.2010.12.001","article-title":"The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1053\/j.gastro.2025.07.004_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.gastro.2025.07.004_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000471879","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging","volume":"105","author":"Sundin","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.gastro.2025.07.004_bib28","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41574-018-0082-5","article-title":"Role of biomarker tests for diagnosis of neuroendocrine tumours","volume":"14","author":"Hofland","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1053\/j.gastro.2025.07.004_bib29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","article-title":"Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites","volume":"34","author":"Sadowski","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2967\/jnumed.116.180430","article-title":"Head-to-head comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET\/CT: a prospective study of 59 patients with neuroendocrine tumors","volume":"58","author":"Johnbeck","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.gastro.2025.07.004_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","author":"Hope","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.gastro.2025.07.004_bib32","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.2967\/jnumed.120.257808","article-title":"Updates to the appropriate-use criteria for somatostatin receptor PET","volume":"61","author":"Hope","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.gastro.2025.07.004_bib33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.gtc.2022.06.002","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"51","author":"Fernandes","year":"2022","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1053\/j.gastro.2025.07.004_bib34","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1016\/j.cgh.2023.01.037","article-title":"Epidemiology of gastric malignancies 2000-2018 according to histology: a population-based analysis of incidence and temporal trends","volume":"21","author":"Rustgi","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.07.004_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13306","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3","volume":"35","author":"Panzuto","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"10.1053\/j.gastro.2025.07.004_bib36","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/his.14220","article-title":"Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis","volume":"77","author":"Trinh","year":"2020","journal-title":"Histopathology"},{"key":"10.1053\/j.gastro.2025.07.004_bib37","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s10620-015-4014-0","article-title":"Solitary gastric carcinoid tumor associated with long-term use of omeprazole: a case report and review of the literature","volume":"61","author":"Nandy","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2025.07.004_bib38","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12328-024-01969-0","article-title":"Multiple gastric neuroendocrine tumors in a patient with parietal cell dysfunction and adenosine triphosphatase H(+)\/K(+) transporting subunit alpha gene variant","volume":"17","author":"Sasaki","year":"2024","journal-title":"Clin J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.07.004_bib39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.gie.2019.06.029","article-title":"Enterochromaffin-like cell neuroendocrine tumor associated with parietal cell dysfunction","volume":"90","author":"Ishioka","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"10.1053\/j.gastro.2025.07.004_bib40","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s12328-022-01704-7","article-title":"A rare case of an enterochromaffin-like neuroendocrine tumor associated with parietal cell dysfunction treated using endoscopic submucosal dissection","volume":"15","author":"Shiroma","year":"2022","journal-title":"Clin J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.07.004_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6679397","article-title":"Comparison of endoscopic techniques in the management of Type I gastric neuroendocrine neoplasia: a systematic review","volume":"2021","author":"Panzuto","year":"2021","journal-title":"Gastroenterol Res Pract"},{"key":"10.1053\/j.gastro.2025.07.004_bib42","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s11605-021-04997-0","article-title":"Clinical outcomes of endoscopic treatment for Type 1 gastric neuroendocrine tumor","volume":"25","author":"Noh","year":"2021","journal-title":"J Gastrointest Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib43","first-page":"1524","article-title":"Usefulness of endoscopic submucosal dissection for type I gastric carcinoid tumors compared with endoscopic mucosal resection","volume":"60","author":"Sato","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"10.1053\/j.gastro.2025.07.004_bib44","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12020-022-03143-3","article-title":"Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter","volume":"78","author":"Exarchou","year":"2022","journal-title":"Endocrine"},{"key":"10.1053\/j.gastro.2025.07.004_bib45","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000510962","article-title":"Selective resection of Type 1 gastric neuroendocrine neoplasms and the risk of progression in an endoscopic surveillance programme","volume":"38","author":"Chin","year":"2021","journal-title":"Dig Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib46","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.dld.2021.11.012","article-title":"Management of type-I gastric neuroendocrine neoplasms: a 10-years prospective single centre study","volume":"54","author":"Esposito","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.gastro.2025.07.004_bib47","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1053\/j.gastro.2021.06.078","article-title":"AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review","volume":"161","author":"Shah","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.07.004_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020662","article-title":"Proton pump inhibitor use, hypergastrinemia, and gastric carcinoids-what is the relationship?","volume":"21","author":"McCarthy","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.gastro.2025.07.004_bib49","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/den.13778","article-title":"Is endoscopic resection appropriate for type 3 gastric neuroendocrine tumors? Retrospective multicenter study","volume":"33","author":"Hirasawa","year":"2021","journal-title":"Dig Endosc"},{"key":"10.1053\/j.gastro.2025.07.004_bib50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5946\/ce.2017.181","article-title":"Diagnosis and management of upper gastrointestinal neuroendocrine tumors","volume":"50","author":"Chin","year":"2017","journal-title":"Clin Endosc"},{"key":"10.1053\/j.gastro.2025.07.004_bib51","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s11605-017-3448-4","article-title":"Duodenal and ampullary carcinoid tumors: size predicts necessity for lymphadenectomy","volume":"21","author":"Dogeas","year":"2017","journal-title":"J Gastrointest Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib52","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s11605-023-05800-y","article-title":"Surgical and endoscopic resection of duodenal neuroendocrine tumors have similar disease-specific survival outcome","volume":"27","author":"Mirzaie","year":"2023","journal-title":"J Gastrointest Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11605-014-2456-x","article-title":"Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors","volume":"18","author":"Untch","year":"2014","journal-title":"J Gastrointest Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib54","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.surg.2005.09.016","article-title":"Carcinoid tumors of the duodenum","volume":"138","author":"Mullen","year":"2005","journal-title":"Surgery"},{"key":"10.1053\/j.gastro.2025.07.004_bib55","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cgh.2023.10.033","article-title":"Expanding role of gastroenterology in the staging of digestive neuroendocrine tumors: updates from the American Joint Committee on Cancer Version 9 Cancer Staging System","volume":"22","author":"Ge","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.07.004_bib56","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000443168","article-title":"ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms","volume":"103","author":"Delle Fave","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.gastro.2025.07.004_bib57","doi-asserted-by":"crossref","first-page":"E302","DOI":"10.1055\/a-0684-9563","article-title":"Endoscopic banding without resection (BWR) technique for treatment of diminutive neuroendocrine tumors in the duodenum","volume":"7","author":"Khara","year":"2019","journal-title":"Endosc Int Open"},{"key":"10.1053\/j.gastro.2025.07.004_bib58","doi-asserted-by":"crossref","first-page":"E717","DOI":"10.1055\/a-1119-6698","article-title":"The band and slough technique is effective for management of diminutive type 1 gastric and duodenal neuroendocrine tumors","volume":"8","author":"Hawa","year":"2020","journal-title":"Endosc Int Open"},{"key":"10.1053\/j.gastro.2025.07.004_bib59","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/a-1751-5742","article-title":"Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline","volume":"54","author":"Deprez","year":"2022","journal-title":"Endoscopy"},{"key":"10.1053\/j.gastro.2025.07.004_bib60","first-page":"5","article-title":"A155 outcomes following endoscopic resection of duodenal neuroendocrine tumours from a tertiary-care academic centre","volume":"6","author":"Gupta","year":"2023","journal-title":"J Can Assoc Gastroenterol"},{"key":"10.1053\/j.gastro.2025.07.004_bib61","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12029-020-00577-8","article-title":"Endoscopic management of diminutive duodenal neuroendocrine tumors","volume":"52","author":"Klemm","year":"2021","journal-title":"J Gastrointest Cancer"},{"key":"10.1053\/j.gastro.2025.07.004_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-19738-9","article-title":"Diagnostic features and management options for duodenal neuroendocrine neoplasms: a retrospective, multi-centre study","volume":"12","author":"Mandair","year":"2022","journal-title":"Sci Rep"},{"issue":"Suppl","key":"10.1053\/j.gastro.2025.07.004_bib63","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.2021.39.3_suppl.373","article-title":"Ampullary neuroendocrine tumors: a window into a rare tumor using a national database","volume":"39","author":"Ruff","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib64","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11605-013-2365-4","article-title":"Clinical outcomes for neuroendocrine tumors of the duodenum and ampulla of Vater: a population-based study","volume":"18","author":"Randle","year":"2014","journal-title":"J Gastrointest Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib65","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1159\/000531712","article-title":"Endoscopic and surgical management of non-metastatic ampullary neuroendocrine neoplasia: a multi-institutional Pancreas2000\/EPC Study","volume":"113","author":"Karam","year":"2023","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.gastro.2025.07.004_bib66","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1055\/s-0042-112570","article-title":"Endoscopic treatment of sporadic small duodenal and ampullary neuroendocrine tumors","volume":"48","author":"Gincul","year":"2016","journal-title":"Endoscopy"},{"key":"10.1053\/j.gastro.2025.07.004_bib67","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00535-014-0934-2","article-title":"Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis","volume":"50","author":"Ito","year":"2015","journal-title":"J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.07.004_bib68","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/ajg.2009.747","article-title":"Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases","volume":"105","author":"Zerbi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.07.004_bib69","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","article-title":"Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival","volume":"19","author":"Halfdanarson","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib70","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.gie.2014.12.031","article-title":"Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis","volume":"81","author":"James","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1053\/j.gastro.2025.07.004_bib71","article-title":"Role of endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in the diagnosis of pancreatic cancer","volume":"11","author":"Ishii","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.gastro.2025.07.004_bib72","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.pan.2023.05.002","article-title":"Endoscopic ultrasound fine-needle biopsy to assess DAXX\/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors","volume":"23","author":"Mastrosimini","year":"2023","journal-title":"Pancreatology"},{"key":"10.1053\/j.gastro.2025.07.004_bib73","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.pan.2020.12.015","article-title":"Comparison between EUS-guided fine-needle aspiration cytology and EUS-guided fine-needle biopsy histology for the evaluation of pancreatic neuroendocrine tumors","volume":"21","author":"Crin\u00f2","year":"2021","journal-title":"Pancreatology"},{"key":"10.1053\/j.gastro.2025.07.004_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"10.1053\/j.gastro.2025.07.004_bib75","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.surg.2012.08.038","article-title":"Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management","volume":"152","author":"Lee","year":"2012","journal-title":"Surgery"},{"key":"10.1053\/j.gastro.2025.07.004_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","article-title":"The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors","volume":"49","author":"Howe","year":"2020","journal-title":"Pancreas"},{"key":"10.1053\/j.gastro.2025.07.004_bib77","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/bjs\/znab088","article-title":"Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA)","volume":"108","author":"Heidsma","year":"2021","journal-title":"Br J Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib78","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/bjs\/znac267","article-title":"Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial","volume":"109","author":"Partelli","year":"2022","journal-title":"Br J Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib79","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1016\/j.cgh.2023.02.022","article-title":"Endoscopic ultrasound-guided radiofrequency ablation versus surgical resection for treatment of pancreatic insulinoma","volume":"21","author":"Crin\u00f2","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.07.004_bib80","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"key":"10.1053\/j.gastro.2025.07.004_bib81","doi-asserted-by":"crossref","first-page":"818","DOI":"10.5946\/ce.2020.296","article-title":"The role of endoscopy in small bowel neuroendocrine tumors","volume":"54","author":"Yoon","year":"2021","journal-title":"Clin Endosc"},{"key":"10.1053\/j.gastro.2025.07.004_bib82","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13423","article-title":"European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"10.1053\/j.gastro.2025.07.004_bib83","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MPA.0b013e3181bc0e77","article-title":"Biochemical testing for neuroendocrine tumors","volume":"38","author":"Vinik","year":"2009","journal-title":"Pancreas"},{"key":"10.1053\/j.gastro.2025.07.004_bib84","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JOP.18.00135","article-title":"Management of small bowel neuroendocrine tumors","volume":"14","author":"Scott","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1053\/j.gastro.2025.07.004_bib85","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"key":"10.1053\/j.gastro.2025.07.004_bib86","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000443170","article-title":"ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum","volume":"103","author":"Niederle","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.gastro.2025.07.004_bib87","doi-asserted-by":"crossref","first-page":"151","DOI":"10.15403\/jgld.2014.1121.262.wce","article-title":"The role of wireless capsule endoscopy (WCE) in the detection of occult primary neuroendocrine tumors","volume":"26","author":"Furnari","year":"2017","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1053\/j.gastro.2025.07.004_bib88","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1007\/s10620-008-0456-y","article-title":"Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy","volume":"54","author":"Bellutti","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2025.07.004_bib89","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1245\/s10434-018-6676-2","article-title":"The distal predilection of small bowel neuroendocrine tumors","volume":"25","author":"Keck","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib90","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00268-010-0428-1","article-title":"Prophylactic cholecystectomy in midgut carcinoid patients","volume":"34","author":"Norl\u00e9n","year":"2010","journal-title":"World J Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib91","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The surgical management of small bowel neuroendocrine tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas"},{"key":"10.1053\/j.gastro.2025.07.004_bib92","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djx174","article-title":"Analysis of postoperative recurrence in Stage I-III midgut neuroendocrine tumors","volume":"110","author":"Cives","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2025.07.004_bib93","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1002\/cncr.10589","article-title":"Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998","volume":"94","author":"McCusker","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.gastro.2025.07.004_bib94","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13332","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET)","volume":"35","author":"Kaltsas","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"10.1053\/j.gastro.2025.07.004_bib95","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(22)00750-1","article-title":"Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1\u20132 cm in size: a retrospective, Europe-wide, pooled cohort study","volume":"24","author":"Nesti","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib96","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2050640619865113","article-title":"Change in incidence, characteristics and management of colorectal neuroendocrine tumours in the Netherlands in the last decade","volume":"8","author":"Kooyker","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"10.1053\/j.gastro.2025.07.004_bib97","doi-asserted-by":"crossref","first-page":"836","DOI":"10.21037\/jgo-20-193","article-title":"Factors associated with worse outcomes for colorectal neuroendocrine tumors in radical versus local resections","volume":"11","author":"Osagiede","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib98","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s11605-020-04525-6","article-title":"Outcomes for a large cohort of patients with rectal neuroendocrine tumors: an analysis of the National Cancer Database","volume":"25","author":"Zhao","year":"2021","journal-title":"J Gastrointest Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib99","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.gie.2018.11.010","article-title":"Prevalence of metastasis and survival of 788 patients with T1 rectal carcinoid tumors","volume":"89","author":"Ngamruengphong","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"10.1053\/j.gastro.2025.07.004_bib100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12957-024-03379-5","article-title":"Impact of grade on workup of rectal neuroendocrine tumors: a retrospective cohort study: grade impact on workup of rectal NETs","volume":"22","author":"Watanabe","year":"2024","journal-title":"World J Surg Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib101","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13309","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours","volume":"35","author":"Rinke","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"10.1053\/j.gastro.2025.07.004_bib102","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11605-011-1786-1","article-title":"Tumor size and depth predict rate of lymph node metastasis in colon carcinoids and can be used to select patients for endoscopic resection","volume":"16","author":"Al Natour","year":"2012","journal-title":"J Gastrointest Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib103","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00535-022-01877-5","article-title":"Characteristics of colorectal neuroendocrine tumors in patients prospectively enrolled in a Japanese multicenter study: a first report from the C-NET STUDY","volume":"57","author":"Sekiguchi","year":"2022","journal-title":"J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.07.004_bib104","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.gassur.2023.12.016","article-title":"Endoscopic treatments for rectal neuroendocrine tumors: a systematic review and network meta-analysis","volume":"28","author":"Chen","year":"2024","journal-title":"J Gastrointest Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12876-022-02365-z","article-title":"Prognosis of incompletely resected small rectal neuroendocrine tumor using endoscope without additional treatment","volume":"22","author":"Cha","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"10.1053\/j.gastro.2025.07.004_bib106","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/1751-2980.13048","article-title":"Endoscopic submucosal dissection versus endoscopic mucosal resection for rectal carcinoid tumor. A meta-analysis and meta-regression with single-arm analysis","volume":"22","author":"Yong","year":"2021","journal-title":"J Dig Dis"},{"key":"10.1053\/j.gastro.2025.07.004_bib107","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/DCR.0000000000003097","article-title":"Local excision versus radical resection for Grade 2 rectal neuroendocrine tumors: a multicenter propensity score-matched analysis","volume":"67","author":"Zeng","year":"2024","journal-title":"Dis Colon Rectum"},{"key":"10.1053\/j.gastro.2025.07.004_bib108","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00464-021-08527-6","article-title":"Oncological outcomes according to the treatment modality based on the size of rectal neuroendocrine tumors: a single-center retrospective study","volume":"36","author":"Son","year":"2022","journal-title":"Surg Endosc"},{"key":"10.1053\/j.gastro.2025.07.004_bib109","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1007\/s00464-024-10963-z","article-title":"The role of endoscopic ultrasonography for diagnosis of residual rectal neuroendocrine tumor","volume":"38","author":"Kim","year":"2024","journal-title":"Surg Endosc"},{"key":"10.1053\/j.gastro.2025.07.004_bib110","doi-asserted-by":"crossref","first-page":"378","DOI":"10.14309\/ajg.0000000000002516","article-title":"Systematic resection of the visible scar after incomplete endoscopic resection of rectal neuroendocrine tumors","volume":"119","author":"Cheminel","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.07.004_bib111","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1007\/s00464-022-09710-z","article-title":"Long-term clinical outcomes of endoscopic submucosal dissection in rectal neuroendocrine tumors based on resection margin status: a real-world study","volume":"37","author":"Sun","year":"2023","journal-title":"Surg Endosc"},{"key":"10.1053\/j.gastro.2025.07.004_bib112","article-title":"Risk factors and clinical outcomes of incomplete endoscopic resection of small rectal neuroendocrine tumors in southern China: a 9-year data analysis","volume":"11","author":"Zhuang","year":"2023","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"10.1053\/j.gastro.2025.07.004_bib113","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib114","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1053\/j.gastro.2025.07.004_bib115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocrine-Related Cancer"},{"key":"10.1053\/j.gastro.2025.07.004_bib116","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib117","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.surg.2021.03.063","article-title":"A prospective study of carcinoid crisis with no perioperative octreotide","volume":"171","author":"Wonn","year":"2022","journal-title":"Surgery"},{"key":"10.1053\/j.gastro.2025.07.004_bib118","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jso.24563","article-title":"Neuroendocrine liver metastasis: the chance to be cured after liver surgery","volume":"115","author":"Bagante","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib119","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/bjs.6587","article-title":"Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome","volume":"96","author":"Sward","year":"2009","journal-title":"Br J Surg"},{"key":"10.1053\/j.gastro.2025.07.004_bib120","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.surg.2008.08.037","article-title":"Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy","volume":"144","author":"Christante","year":"2008","journal-title":"Surgery"},{"key":"10.1053\/j.gastro.2025.07.004_bib121","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jvir.2008.01.030","article-title":"Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results","volume":"19","author":"de Baere","year":"2008","journal-title":"J Vasc Interv Radiol"},{"key":"10.1053\/j.gastro.2025.07.004_bib122","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","article-title":"Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients","volume":"31","author":"Kennedy","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib123","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO Guideline","volume":"41","author":"Rivero","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib124","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2025.07.004_bib125","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.07.004_bib126","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.07.004_bib127","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.07.004_bib128","series-title":"Lutathera Prescribing Information","year":"2018"},{"key":"10.1053\/j.gastro.2025.07.004_bib129","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.07.004_bib130","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.07.004_bib131","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.07.004_bib132","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.07.004_bib133","series-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol","author":"Kunz","year":"2023"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525057403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525057403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T13:03:01Z","timestamp":1779541381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508525057403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":133,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0016508525057403"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2025.07.004","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastroenteropancreatic Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2025.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}